Newsroom

August 2018

• 
  Story Aug 29, 2018 Patient Perspectives

  The ABCDEs of melanoma prevention and detection

  Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.

• Press release Aug 29, 2018

  European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma

  Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients   More than 50% of stage III melanoma…
• Ad hoc release Aug 29, 2018

  Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma

  Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
• 
  Story Aug 27, 2018 Discovery

  Teaming up with academia to discover medicines

  The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.

• Press release Aug 27, 2018

  Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

  The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
• Press release Aug 27, 2018

  Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission

  Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein…
• Press release Aug 25, 2018

  Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode

  TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1…
• Ad hoc release Aug 23, 2018

  SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

  SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
• 
  Story Aug 21, 2018 From Our Labs

  Neuroscientists target Alzheimer’s “silent stage”

  Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.

• Ad hoc release Aug 14, 2018

  Novartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer

  Basel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D.,  den CEO von…
• Ad hoc release Aug 14, 2018

  Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

  Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
• 
  Story Aug 13, 2018 Discovery

  New drug manufacturing tools change pharma chemistry

  The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.